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ABSTRACT
This Phase I study was performed to assess the feasi-
bility of combining docetaxel with the new P-glycoprotein
inhibitor R101933 and to determine the dose limiting toxic-
ity of this combination. Fifteen patients received oral
R101933 alone at a dose escalated from 200 to 300 mg twice
daily (b.i.d.; cycle 0), an escalating i.v. dose of docetaxel (60,
75, and 100 mg/m2) as a 1-h infusion (cycle 1), and the
combination (cycle 2 and further). Dose limiting toxicity
consisting of mucositis and neutropenic fever was reached at
the combination of docetaxel, 100 mg/m2, and R101933, 300
mg b.i.d., and the maximum tolerated dose was established
at docetaxel, 100 mg/m2, and R101933, 200 mg b.i.d. Plasma
concentrations of R101933 achieved in patients were in the
same range as required in preclinical rodent models to
overcome paclitaxel resistance. The plasma pharmacokinet-
ics of docetaxel were not influenced by the R101933 regimen
at any dose level tested, as indicated by plasma clearance
values of 26.5 6 7.78 liters/h/m2 and 23.4 6 4.52 liters/h/m2
(P 5 0.15) in cycles 1 and 2, respectively. These findings
indicate that the contribution of a P-glycoprotein inhibitor
to the activity of anticancer chemotherapy can now be as-
sessed in patients for the first time independent of its effect
on drug pharmacokinetics.
INTRODUCTION
Acquired or intrinsic resistance of malignant cells to tax-
anes and other naturally occurring drugs has been linked to the
so-called “classical” mechanism of MDR2 resulting in de-
creased intracellular concentrations of these anticancer drugs.
This MDR phenotype is characterized by increased levels of
P-glycoprotein, a member of the ATP-binding cassette super-
family of transmembrane transport proteins with a molecular
weight of Mr 170,000 encoded by the MDR1 gene and acting as
an energy-dependent drug efflux pump with broad substrate
specificity (1, 2).
Since the first observation that verapamil could reverse
MDR in vitro, similar properties have been shown for a wide
range of drugs (3). These agents are thought to be competitive
substrates for P-glycoprotein and thus can increase the intracel-
lular concentration of a coadministered anticancer agent and
consequently restore the antitumoral activity (4). Initially, a
number of drugs, marketed for other indications than inhibiting
P-glycoprotein, have entered clinical trials (5). However, it
became evident that pharmacokinetic interactions occurred be-
tween these P-glycoprotein inhibitors and the coadministered
anticancer drugs due in part to competitive inhibition of cyto-
chrome P-450 enzymes resulting in significantly increased tox-
icity of the anticancer drug (6). By rational design, new modu-
lators were developed to specifically inhibit P-glycoprotein and
to be more suitable candidates for further clinical evaluations (7,
8). The results of most of these clinical studies have been rather
disappointing, and the pharmacokinetic interaction between the
cytotoxic and the P-glycoprotein inhibiting agent remains a
confounding problem (6, 9).
R101933 (Fig. 1) is a new p.o. administered compound that
inhibits P-glycoprotein as demonstrated by various in vitro and
in vivo models (10, 11). The tolerability, cardiovascular and
laboratory safety, and the pharmacokinetics were investigated in
healthy subjects.3 Nausea and vomiting were the dose-limiting
adverse events and were reported above the 400-mg single oral
dose. Drowsiness was also mentioned as a side effect. No
clinically relevant changes in laboratory and cardiovascular
safety parameters were observed. In vitro metabolism studies
showed that the major metabolic pathway is not cytochrome
P450 3A4-dependent.3 Plasma levels of R101933 at 200 mg
b.i.d. are in the range of concentrations that are active in
paclitaxel and Adriamycin-resistant human tumor xenograph
rodent models.3
Docetaxel is a known substrate of P-glycoprotein and has
shown to have a higher affinity for the protein than the related
compound paclitaxel (12, 13). It also lacks the problems asso-
ciated with i.v. use of paclitaxel caused by the presence of the
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formulation vehicle Cremophor EL, which is known to (a) alter
the pharmacokinetics of the anticancer drug by entrapment in
micelles (14) and (b) mask the effects, if any, of endogenously
expressed P-glycoprotein on the plasma levels of paclitaxel (15).
Therefore, the development of agents that could reverse or
prevent the development of resistance to docetaxel is of great
interest.
The principal objectives of this Phase I and pharmacoki-
netic study of R101933 and docetaxel were to determine the
clinical utility of the combination and to investigate the potential
lack of pharmacokinetic interactions.
PATIENTS AND METHODS
Eligibility. Patients with a histologically confirmed di-
agnosis of a solid tumor for whom docetaxel as monotherapy
was a viable therapeutic option or for whom other treatment
options were not available were candidates for this study. Ad-
ditional eligibility criteria were: age $18 and #75 years; East-
ern Cooperative Oncology Group performance status ,3; life
expectancy of at least 3 months; off previous anticancer therapy
for at least 4 weeks; no previous treatment with taxanes or high
dose chemotherapy requiring progenitor cell support; adequate
bone marrow function (WBC count .3.5 3 109/liter, platelet
count .100 3 109/liter), renal function (serum creatinine #2
times the upper limit of normal), and liver function (bilirubin
level normal, aspartate/alanine aminotransferase #2 times upper
limit of normal, and alkaline phosphatase #2.5 times upper
limit of normal); and symptomatic peripheral neuropathy less
than grade 2 (NCI criteria). Written informed consent was
obtained from all patients, and the study was approved by the
Rotterdam Cancer Institute Ethics Board.
Pretreatment and Follow-up. Pretreatment evaluation
consisted of recording the history of the patient, physical exam-
ination, laboratory studies, electrocardiography, and chest X-
ray. Computer tomographic scans were performed for tumor
measurements. Laboratory studies included a complete blood-
cell count analysis and measurement of WBC differential, elec-
trolytes (including sodium, potassium, chloride, calcium, and
inorganic phosphate), creatinine, urea, alkaline phosphatase,
aspartate aminotransferase, alanine aminotransferase, lactate de-
hydrogenase, bilirubin, total plasma proteins, serum albumin,
glucose, uric acid, and urinalysis. History, physical examination,
and toxicity scoring (according to the NCI-expanded CTC) were
repeated once a week. Complete blood cell counts, including
WBC differential, were performed twice a week, and the other
laboratory tests were done once a week. Electrocardiography
was repeated as clinically indicated. A final assessment was to
be made after patients went off the study. Formal tumor meas-
urements and chest X-ray were performed at 6-week intervals
until documentation of PD. Standard WHO response criteria
were used.
Drug Administration. Docetaxel was administered ev-
ery 3 weeks on day 3 as a 1-h infusion and was started 1 h after
intake of R101933. All patients received premedication with
dexamethasone, p.o. 8 mg b.i.d., starting 1 day before each
infusion of docetaxel for 5 days. R101933 (Janssen Research
Foundation, Beerse, Belgium) was supplied as a 10-mg/ml oral
solution in 15% hydroxypropyl-b-cyclodextrin. It had to be
taken with water at least 1 h after a meal. The drug was
administered twice daily from days 1–5. From studies with
healthy volunteers, it was known that the terminal half-life of
R101933 averaged about 24 h, with peak plasma concentrations
attained within 2 h after intake. The MTD after 7-day b.i.d.
dosing was 300 mg in healthy volunteers.3 Seven-day dosing at
200 mg b.i.d. appeared to be safe and well tolerated. Pharma-
cokinetic data revealed that plasma levels of R101933 at 200 mg
b.i.d achieve concentrations that are in the same range as re-
quired in in vivo models to overcome paclitaxel resistance.
Hence, the starting dose for our study was set at this dose level.
In view of the terminal disposition half-life of docetaxel, a
simultaneous exposure to both R101933 and docetaxel for a
3-day period was considered sufficient. This led to the choice of
the 5-day R101933 regimen. In the first stage of the study, the
dose of docetaxel was escalated and the dose of R101933 was
fixed. In the second stage of the study, the dose of docetaxel was
fixed and the dose of R101933 was escalated.
First, the patients received five doses of R101933 alone
every 12 h (cycle 0) followed by a 48-h wash-out to allow
assessment of the terminal half-life of R101933. One week later,
cycle 1 was initiated with docetaxel alone. Thereafter, the com-
bination was given triweekly until PD or DLT occurred.
In each cohort, three patients were treated unless DLTc or
DLTr was observed. In that case, the accrual of three additional
patients was required. DLTc was defined as grade 3 nonhema-
tological toxicity (with the exception of nonhematological tox-
icity that was still manageable in an out-patient setting, such as
nausea/vomiting) or grade 4 neutropenia lasting .8 days or
grade 4 thrombocytopenia or required delay .2 weeks to a
subsequent cycle due to toxicity. Febrile neutropenia and neu-
tropenia with severe infection ($grade 3 infection) was also
considered as DLTc. DLTr was defined as any nonhematologi-
cal toxicity .grade 2 in the first 2 days of treatment before
chemotherapy was given. For dose-escalation decisions, only
DLTs in cycles 0 and 2 were taken into account. The DLT of the
combination of R101933 with docetaxel was reached when
greater or equal to three of six patients experienced DLTc. The
DLT of R101933 alone was reached when greater or equal to
one of three (or greater or equal to two of six) patients experi-
enced DLTr. The MTD was defined as the dose level below
DLT.
Sample Collection and Processing. Blood specimens
were taken in all patients during the first, second, and third
courses of treatment. Blood volumes of 6 ml were drawn di-
Fig. 1 Structure of R101933 (R 5 CH3) and its main metabolite
R102207 (R 5 H).
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rectly into Vacutainer tubes containing lyophilized sodium hep-
arin (Becton Dickinson, Meylan, France) from a peripheral
venous access device. In each patient, sufficient plasma was
obtained before drug administration to evaluate possible inter-
fering peaks in the chromatographic analysis. Samples for do-
cetaxel analysis were collected immediately before infusion and
at 0.5, 1, 1.25, 1.5, 2, 3, 7, 11, 23, and 31 h after the start of
infusion. For the determination of R101933 concentrations,
blood samples were obtained on day 1 (before the first dosing),
day 2 (before the second dosing and 12 h thereafter), and day 3
(before the third dosing and 2, 4, 8, 12, 24, 32, and 48 h
thereafter). All blood samples were centrifuged immediately for
10 min at 1000 3 g to yield plasma, which was stored frozen in
polypropylene vials (Eppendorf, Hamburg, Germany) until the
time of analysis.
Analytical Methods. A pure reference standard of do-
cetaxel (batch, 14PROC9230; purity, 98.0% by reversed-phase
high-performance liquid chromatography) and the clinical do-
cetaxel formulation in polysorbate 80 (Taxotere; 40 mg/ml)
were kindly supplied by Rhoˆne-Poulenc Rorer (Vitry-sur-Seine,
France) and were used as received. Plasma concentrations of
docetaxel were determined by a validated liquid chromatograph-
ic/tandem mass spectrometric assay, with a lowest limit of
quantitation of 1 ng/ml. Samples (200 ml) were pretreated by
solid-phase extraction using endcapped Bond Elut nitrile micro-
columns (Varian, Harbor City, CA), based on an earlier proce-
dure described for paclitaxel (16). A stainless steel analytical
column (100 3 4.6 mm internal diameter) packed with 3-mm
Hypersil BDS C18 material (Alltech, Breda, the Netherlands)
was used for chromatographic separation, and gradient elution
was performed with a mixture of acetonitrile and 0.02 M am-
monium acetate (pH 4.0) at a flow rate of 0.8 ml/min. Paclitaxel
(50 ml of 20 mg/ml in acetonitrile) was used as internal standard.
Triple quadrupole mass-spectrometric detection was performed
with a turboionspray interface used in the positive ion mode
with selective monitoring at m/z 808.5 (molecular ion docetaxel
parent) and m/z 854.5 (molecular ion paclitaxel parent) and at
m/z 527.0 (docetaxel taxane ring fragment) and m/z 569.0 (pa-
clitaxel taxane ring fragment) in the first and third quadrupole,
respectively. Calibration curves spanning a range of 1–5000
ng/ml were calculated by regression analysis of peak area ratios
of docetaxel:internal standard versus the spiked drug concentra-
tion of the standard.
Blood samples collected and processed to plasma were also
analyzed, as appropriate, for R101933 and its esterase-mediated
carboxylic acid metabolite R102207 using a validated high-
performance liquid chromatography method. This assay used a
selective solid-phase extraction with Bond-Elut Certify micro-
columns (Varian). The columns were conditioned with 3 ml of
ethanol, 3 ml of deionized water, and 1 ml of 1 M aqueous acetic
acid. Plasma samples (1 ml) were mixed with three volumes of
1 M acetic acid and 100 ml of the internal standard (R125026; 10
mg/ml in acetonitrile) and then loaded on the extraction col-
umns. Consecutive washing steps with 3 ml of deionized water,
1 ml of 1 M acetic acid, and 3 ml of ethanol were performed
before elution in 3 ml of ethanol:ammonia (98:2, v/v). Samples
were dried under nitrogen at 65°C and reconstituted in 100 ml of
0.02 M ammonium formate (pH 4.0):acetonitrile:ethanol (50:25:
25, v/v/v). The analytes were separated on a 3-mm Hypersil
BDS C8 column (100 3 4.6 mm internal diameter; Alltech)
using a mobile phase comprising 0.02 M ammonium formate
(pH 4.0), acetonitrile, and ethanol delivered with gradient elu-
tion at 0.8 ml/min. Detection was performed by UV absorption
measurements at 270 nm. The concentrations of R101933 and
R102207 were determined from calibration curves constructed
in blank human plasma in the range of 2–10,000 ng/ml. The
ratio of the log-transformed peak areas of each of the analytes:
internal standard were plotted versus nominal concentrations for
quantitative computations.
Pharmacokinetic Data Analysis. Individual plasma
concentration-time profiles of R101933 and its inactive metab-
olite R102207 were analyzed model independently using a
validated macro in the EXCEL software package. The actual
times of drug intake and blood sampling were taken into ac-
count. Peak plasma concentration (Cmax) was determined by
visual inspection of the data. The AUC within a 12-h dosing
interval was calculated by the trapezoidal rule. In all cases, the
AUC was extrapolated to infinity by addition of Clast/l, in
which Clast is the last quantifiable concentration in the curve and
l is the terminal elimination rate constant determined by linear
regression analysis of the terminal points of the ln-linear plasma
concentration-time curve. The terminal disposition half-life
[t1/2(2)] was defined as ln2/l. Individual plasma concentration-
time curves of docetaxel were analyzed using the software
package WinNonlin (Pharsight, Mountain View, CA) by deter-
mining the slopes and intercepts of the plotted curves with
multiexponential functions. All curves were fitted using the
actual infusion duration and blood sampling times. In all cases,
concentration-time profiles of docetaxel were best fitted to a
biexponential equation after zero-order input with weighting
according to the square of the model predictions of the concen-
trations. Final values of the iterated parameters of the best-fit
function were used to calculate the pharmacokinetic parameters
using standard equations (17).
Statistical Considerations. Pharmacokinetic parameters
for docetaxel and R101933 are reported as mean values 6 SD.
Variability in dose-normalized parameters between the various
docetaxel dose levels was evaluated by the Kruskal-Wallis
statistic followed, if required, by a Dunn’s test to determine
which group differed. To test pharmacodynamic and pharmaco-
kinetic parameter differences for statistical significance among
treatment courses, a two-tailed paired Student’s t test was per-
formed. Probability values of ,0.05 were regarded as statisti-
cally significant. All statistical calculations were performed
using the Number Cruncher Statistical System version 5.X (Dr.
Jerry Hintze, Kaysville, UT; 1992) or using Statgraphics Plus
version 2 (Manugistics Inc., Rockville, MA).
RESULTS
Seventeen patients were entered into this study. Patient
characteristics are listed in Table 1; all patients were eligible.
Two patients were considered not evaluable for toxicity and
response. They did not receive the combination therapy, one
because of unexpected rapid deterioration of the clinical condi-
tion and another because of development of liver enzyme ab-
normalities due to the malignant disease that would have pre-
cluded administration of docetaxel within normal safety limits.
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At the dose level for R101933, 300 mg b.i.d., one patient was
not evaluable for pharmacokinetics because it was not possible
to take blood samples during the second cycle for technical
reasons.
Toxicity and Pharmacodynamics. A total of 59 cycles,
including 44 cycles of combined docetaxel and R101933, were
given. Table 2 lists the number of cycles at each dose level and
the main toxicities at each dose level. In the first part of the
study, the dose of docetaxel was escalated and the dose of
R101933 was fixed at 200 mg b.i.d. Each dose level of do-
cetaxel, 60, 75, and 100 mg/m2 respectively, consisted of three
patients, and no DLT was experienced at this stage. One patient
at the dose level of 60 mg/m2 was hospitalized because of
neutropenic fever after cycle 3 and was diagnosed to have
pneumonia and sinusitis. Because of this clearly unrelated focus,
the patient received two further cycles, which were uneventful.
Two patients had grade 2 diarrhea starting 1 week after do-
cetaxel infusion lasting not more than 4 days. Due to infection
occurring in the area of the primary head/neck tumor after cycle
0, one patient treated with docetaxel at a dose level of 100
mg/m2 was given prophylactic antibiotics during both cycles 1
and 2. From all three dose levels of docetaxel studied with
R101933, 200 mg b.i.d., it was concluded that the combination
was feasible with docetaxel given up to 100 mg/m2, which is the
single agent MTD for docetaxel (12).
In the second part of the study, the dose of docetaxel was
fixed at 100 mg/m2 and the dose of R101933 was escalated to
300 mg b.i.d. Paired analysis of hematological pharmacody-
namic parameters indicated that R101933 coadministration had
no significant influence on the observed myelotoxicity (Table
3), including the percent decrease in WBC and absolute neutro-
phil count. DLTs were seen in four of six patients, but in two of
these already with single treatment of docetaxel, and thus
could not be attributed to the combination (Table 4). DLT
consisted of neutropenic fever (n 5 2), mucositis (n 5 1), and
vomiting (n 5 1).
DLTr was not reached at any of the investigated dose
levels. Nausea/vomiting and drowsiness, known to be side ef-
fects of R101933 in healthy subjects,3 were not seen in our
patients after administration of R101933 alone. Fatigue was
often mentioned as a side effect after docetaxel but never
exceeded grade 2. Nevertheless, for one patient given docetaxel
at 100 mg/m2 and R101933, 200 mg b.i.d., it was a reason to
refuse further treatment after cycle 3, although an ongoing
partial response was noted. Two patients at docetaxel 100
mg/m2 and R101933, 300 mg b.i.d., went off the study after
cycle 2 because of the observed DLT consisting of mucositis
and vomiting, respectively. All other patients went off the study
because of PD. Two patients achieved a partial response, and
seven had stable disease.
Plasma Pharmacokinetics. For the evaluation of do-
cetaxel pharmacokinetics, only the patients who had sampling
and complete kinetic data during both treatment courses were
included (n 5 14 of 15). The results of paired plasma concen-
tration-time profiles of unchanged docetaxel given with and
without cotreatment were remarkably similar for all patients
studied (Fig. 2). During both treatment courses, disposition
phases appeared to be very typical of a biexponential profile,
with plasma concentrations of docetaxel decreasing very rapidly
immediately after cessation of the infusion, followed by a more
prolonged terminal disposition phase of ;11 h, in line with
previous observations (18). The mean pharmacokinetic param-
eters of docetaxel for both treatment courses are summarized as
a function of the study cohort in Table 5. The docetaxel total
body clearance was normally distributed as judged by the
D’Agostino-Pearson omnibus K2 test, was independent of the
administered dose (Kruskal-Wallis, P 5 0.396), and averaged
26.5 6 7.78 liters/h/m2 (mean 6 SD) without R101933 and
23.4 6 4.52 liters/h/m2 with R101933 (Kruskal-Wallis, P 5
0.608), which is within the same range as described for this
compound previously (18). There were no statistically signifi-
cant differences in any of the studied docetaxel pharmacokinetic
parameters, including the clearance (P 5 0.15), between the two
treatment courses (Table 5), suggesting that R101933 adminis-
tration did not influence the disposition of the taxane at the dose
levels tested. At the final dose level, combining docetaxel at 100
mg/m2 and R101933, 300 mg b.i.d, statistical analysis indicated
that a 1.3-fold change in docetaxel clearance could have been
detected with (1-b) 5 0.80 at the observed SD of the mean
difference between cycles (sd 5 3.13) and a calculated stan-
dardized difference of 2d/sd (19).
Similarly, docetaxel did not significantly alter the absorp-
tion and elimination routes of R101933 (Table 6). In addition,
dose-normalized AUC values for R101933 were similar with or
without docetaxel cotreatment. Overall, substantial interpatient
variability in R101933 kinetic parameters was apparent, with up
to a 10-fold variation in peak plasma levels. Over the total dose
range studied, the peak plasma levels of R101933 did not
increase with values of 133 6 74 ng/ml (mean 6 SD; n 5 10)
and 136 6 45 ng/ml (n 5 7) respectively, suggesting a dose-
dependent kinetic behavior of the compound with saturable
absorption characteristics. For this reason, no attempt was made
to further increase the dose of R101933. In all patients, there
was extensive formation of the pharmacologically inactive com-
pound R102207, the principal circulating metabolite of
Table 1 Patient characteristics
Characteristic No.
Patients included 17
Sex
Male 10
Female 7
Age, yr
Median 57.5
Range 42–72
Performance score (WHO)
0 8
1 9
Primary tumor
Urogenital tract 6
Gastrointestinal tract 5
Respiratory tract 2
Melanoma 2
Sarcoma 1
Unknown primary 1
Prior therapy
Surgery 14
Radiotherapy 7
Chemotherapy 11
None 1
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R101933, reaching AUC values ;80-fold higher than that of the
parent compound. Concentrations of this compound were also
not substantially influenced by the administration of docetaxel
at any dose level tested (Table 6). Of particular note, plasma
levels of R101933 capable of reversal of daunorubicin resist-
ance in A2780 cell cultures with and without P-glycoprotein
expression were achieved in all patients (20).
DISCUSSION
In the present study, we observed that the plasma pharma-
cokinetic characteristics of docetaxel were not substantially
influenced by R101933, a new p.o. administered P-glycoprotein
inhibitor. The lack of a pharmacokinetic interaction between
docetaxel and R101933 is an important finding that makes it
possible to study the contribution of an inhibitor of P-glycopro-
tein to the toxicity and activity of an anticancer drug independ-
Table 2 Main toxicities (worst per cycle) at each dose level expressed in number of cycles in which they occurred
Docetaxel
mg/m2
R101933
mg b.i.d.
No. pts/
cycle
Neutropenia CTC
gradea
Neutropenic
fever
Vomiting
CTC grade
Mucositis CTC
grade
Fatigue
CTC grade
DLTc0 1 2 3 4 0 1 2 3 4 0 1 2 3 0 1 2
60 200 3/11 4 5 2 1 10 1 11 6 5 0
75 200 3/18 1 1 6 3 7 17 1 16 2 10 6 2 0
100 200 3/7 2 5 2 7 5 1 1 2 1 4 0
100 300 6/23 1 1 2 3 16 4 20 1 2 17 3 2 1 12 7 4 4
a NCI CTC.
Table 3 Summary of hematological pharmacodynamicsa
Parameter Cycle 1 Cycle 2 and further Mean difference 95% C.L.b Pc
Leukocytes
Nadir (3 109/liter) 1.51 6 1.00 2.23 6 1.82 20.72 6 0.35 21.48, 0.038 0.061
(0.43–3.40) (0.20–7.30)
% decrease WBC 75.2 6 18.0 70.9 6 17.7 4.28 6 4.41 25.18, 13.7 0.348
(33.3–96.6) (37.9–96.9)
Neutrophils
Nadir (3 109/liter) 0.44 6 0.49 0.64 6 0.86 20.20 6 0.17 20.57, 0.18 0.274
(0.04–1.50) (0.05–2.60)
% decrease ANC 90.6 6 9.48 88.6 6 15.7 2.06 6 3.89 26.50, 10.6 0.607
(75.6–99.3) (44.8–98.7)
a Data were obtained from patients after treatment with a 1-h i.v. infusion of docetaxel at a dose level of 60, 75, or 100 mg/m2 given either alone
(cycle 1) or in the presence of oral R101933 at a dose level of 200 or 300 mg b.i.d. (cycle 2 and further). The relative hematological toxicity (i.e.,
the percentage decrease in blood cell count) was defined as: % decrease 5 [(pretherapy value 2 nadir value)/(pretherapy value)] 3 100%. Data are
presented as mean values 6 SD, with the observed range shown in parenthesis.
b C.L., 95% confidence limits for the mean difference; ANC, absolute neutrophil count.
c Paired Student’s t test.
Table 4 Neutropenia [highest CTC grade (NCI common toxicity
criteria)] and DLT as per protocol in cycle 1 versus cycle 2 and
further
Taxotere
(mg/m2)
R101933
(mg b.i.d.) Patient
Cycle 1 Cycle 2 and further
Neutropenia DLT Neutropenia DLT
60 200 1 2 2 0 2
2 2 2 4 2
3 2 2 0 2
75 200 4 4 2 4 2
5 4 2 4 2
6 4 2 3 2
100 200 7 4 2 4 2
8 4 2 4 2
9 4 2 2 2
100 300 10 4 2 4 1
11 4 2 4 2
12 4 1 4 2
13 0 2 4 1
14 4 1 4 1
15 4 2 4 2
Fig. 2 Plasma concentration versus time profiles of docetaxel in pa-
tients treated with 100 mg/m2 of docetaxel alone (E) or in combination
with 300 mg b.i.d. oral R101933 (F). Data are presented as mean values
(E, F) 6 SD (error bars).
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ently of its effects on drug pharmacokinetics. Previous clinical
studies have shown that drug interactions between modulator
and anticancer drugs occur (even with dose reductions of the
anticancer drug), resulting in increased toxicity that can be
accounted for by pharmacokinetic interactions alone [reviewed
in Ref. (6)]. These clinical investigations indicate that P-glyco-
protein inhibitors [verapamil, cyclosporin A, PSC833 (valspo-
dar), and VX-710 (biricodar)] increase the anticancer drug’s
systemic exposure, thereby potentially (nonselectively) increas-
ing exposure to normal and malignant cells, resulting in in-
creased severity or incidence of toxic adverse effects. Based on
these findings, it has been proposed that the administration of
P-glycoprotein inhibitors is unlikely to improve the therapeutic
index of docetaxel (or any other drug) without dose adjustment
unless such agents lack a pharmacokinetic interaction (6, 9).
Our findings show that previously observed drug pharma-
cokinetic interactions between anticancer drugs and modulators,
such as those between the docetaxel analogue paclitaxel and
r-verapamil (21), cyclosporin A (22), PSC833 (23), or VX-710
(24), are most likely more related to an overlap in specificity of
enzymes responsible for metabolism of the compounds than to
modulation of P-glycoprotein activity. Although few clinical
data are available, several in vitro studies have shown that
docetaxel is extensively metabolized in humans by the cyto-
chrome P450 3A4 system (25, 26). The main pathway of do-
cetaxel metabolism in humans consists of successive oxidations
of the tert-butyl propionate group on the C13 side chain, with
spontaneous cyclization occurring for the putative aldehyde and
acid derivatives. All metabolites thus far characterized have
been found to be .100-fold less cytotoxic than docetaxel itself
(27, 28). In this context, it is noteworthy that R101933 did not
influence the in vitro metabolism of docetaxel even at concen-
trations as high as 1 mg/ml and that the major metabolic route to
R102207 is cytochrome-P450-unrelated.3 Clearly, additional
experiments are needed to establish the relevance of this prin-
ciple in humans and to determine for what drugs it will apply. In
addition, when given in combination with docetaxel, biologi-
cally relevant R101933 concentrations could be achieved and
sustained for several hours, simulating optimal pharmacological
conditions required for complete reversal of the MDR pheno-
type in in vitro systems.
Clinically, we observed that single treatment with R101933
given p.o. at the tested dosages was associated with minimal
toxicity. The toxicological profile of the combination appeared
to be very similar to that reported for docetaxel alone and
included neutropenic fever and mucositis as the principal DLTs.
Febrile neutropenia requiring hospitalization has been reported
in ;15% and severe mucositis in ;10% of cases treated with
docetaxel alone (29). In fact, the incidence of neutropenia ob-
served with other inhibitors of P-glycoprotein in studies with
anticancer drugs is greater than that observed with the cytotoxic
agent alone (24). Fatigue was often mentioned by the patients in
this study as a side effect, but never after R101933 alone, and
asthenia is also a known side effect of docetaxel.
In conclusion, we have shown that the studied combination
Table 5 Plasma pharmacokinetic parameters of docetaxel in the absence or presence of R101933a
Cohort AUC (mgzh/ml) Cmax (mg/ml) t1/2(a)b (h) t1/2(z) (h) Vdss (liters/m2) MRT (h)
Docetaxel
60 mg/m2 (n 5 3)
Without R 3.18 6 0.95 2.06 6 0.58 0.17 6 0.02 12.5 6 3.8 120 6 43 6.21 6 2.78
With R, 200 mg 2.88 6 0.52 1.77 6 0.27 0.20 6 0.01 11.3 6 0.4 119 6 35 5.54 6 1.08
Docetaxel
75 mg/m2 (n 5 3)
Without R 2.83 6 1.03 1.68 6 1.01 0.37 6 0.36 12.0 6 2.4 253 6 227 7.49 6 3.34
With R, 200 mg 3.59 6 0.30 2.20 6 0.53 0.32 6 0.12 12.1 6 2.5 112 6 29 5.31 6 1.22
Docetaxel
100 mg/m2 (n 5 3)
Without R 3.93 6 0.67 2.47 6 0.21 0.15 6 0.06 11.1 6 2.3 137 6 27 5.51 6 1.92
With R, 200 mg 4.33 6 1.13 2.95 6 0.26 0.24 6 0.06 9.4 6 4.4 86 6 41 3.78 6 2.05
Docetaxel
100 mg/m2 (n 5 5)
Without R 3.62 6 0.71 2.54 6 0.54 0.18 6 0.03 11.0 6 2.0 129 6 32 4.59 6 0.95
With R, 300 mg 4.04 6 0.84 2.86 6 0.55 0.23 6 0.07 10.9 6 4.8 104 6 50 4.27 6 2.02
a Data were obtained from patients after the first (without R101933) and second treatment cycle (with R101933) of a 1-h infusion of docetaxel.
The kinetic terms are mean values 6 SD.
b t1/2(i), half-life of the i-th disposition phase; Vdss, volume of distribution at steady state; MRT, mean residence time; n, number of patients
evaluated at both treatment courses; R, R101933.
Table 6 Plasma pharmacokinetic parameters of R101933 and its
metabolite R102207 in the absence or presence of docetaxela
Parameter
200 mg of R101933
(n 5 9)b
300 mg of R101933
(n 5 5)
Without D With D Without D With D
R101933
Cmax
(ng/ml)
120 6 66 94.3 6 26.9 127 6 50 144 6 42
t1/2(z) (h) 19.6 6 7.4 NA 23.0 6 9.2 NA
AUC
(mgzh/ml)
0.55 6 0.24 0.53 6 0.15 0.91 6 0.46 0.86 6 0.49
R102207
AUC
(mgzh/ml)
50.5 6 14.2 52.4 6 26.7 37.9 6 20.2 45.7 6 11.0
a Data were obtained from patients after cycle 0 (without
docetaxel) and after cycle 2 (with docetaxel). The kinetic terms are mean
values 6 SD.
b n, number of patients evaluated; D, docetaxel; NA, not available.
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of oral R101933 and i.v. docetaxel is safe and at the achieved
dose levels, lacks the significant kinetic interaction with the
anticancer drug as observed previously with other modulators.
In the case of a Phase II/III study with the combination of
R101933 and docetaxel, 100 mg/m2, and in view of the phar-
macokinetic data on R101933 presently presented, the recom-
mended dose of R101933 will be 200 mg b.i.d. p.o.
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